Moderna Secures Deal to Provide 12.5 Million COVID-19 Vaccines for Brazil’s National Vaccination Drive
Moderna, Inc. (NASDAQ: MRNA) has announced a significant milestone in its global efforts to combat COVID-19 by securing a contract with Brazil’s Ministry of Health (Ministério da Saúde). The contract…
Our commitment to reducing plastic waste
In April, we annually commemorate Earth Day, underscoring the collaborative endeavor required to forge a healthier environment for the forthcoming generations. This year’s Earth Day theme, “Planet versus Plastics,” spotlights…
Bristol Myers Squibb & Cellares Strike $380M Deal to Boost CAR T Cell Therapy Production
Bristol Myers Squibb (NYSE: BMY) and Cellares, the pioneering Integrated Development and Manufacturing Organization (IDMO) dedicated to cell therapy manufacturing, have announced a significant worldwide capacity reservation and supply agreement.…
European Commission Clears Pfizer’s EMBLAVEO® for Multidrug-Resistant Infections
Pfizer Inc. (NYSE: PFE) has received approval from the European Commission (EC) for EMBLAVEO® (aztreonam-avibactam), expanding treatment options for adult patients facing complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including…
Lilly Purchases New Injectable Medicine Plant from Nexus Pharmaceuticals
Eli Lilly and Company (NYSE: LLY) and Nexus Pharmaceuticals, LLC have announced a definitive agreement for Lilly to acquire a manufacturing facility from Nexus, a prominent sterile manufacturer in the…
Astellas Verifies Unfavourable District Court Ruling on Preliminary Injunction Against Lupin and Zydus’ MyrbetriqTM Generics
Astellas Pharma Inc. has confirmed that the U.S. District Court for the District of Delaware has issued a Report and Recommendation advising against granting Astellas’ motion for a preliminary injunction.…
Notice from NYSE American Received by NovaBay Pharmaceuticals Regarding Stockholder Equity
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reported today that it has received a notice from the NYSE American LLC, dated April 18, 2024, indicating that the Company is currently below…
Grifols Marks 50 Years of Transformative Plasma Medicine Production in Clayton, N.C
Grifols, a global healthcare leader renowned for its plasma-derived medicines, commemorated the 50th anniversary of its Clayton, N.C. flagship facility today. Since its inception, this site has been pivotal in…
Shionogi Shows Fetcroja’s Effectiveness in Tough Infections: Real-World Data
Shionogi & Co., Ltd. unveiled groundbreaking findings from the largest European real-world evidence study, PERSEUS, at the 34th ESCMID Global (formerly ECCMID) conference in Barcelona from April 27th to 30th,…
Bayer Inks Renewable Energy Supply Deal with Wuppertaler Stadtwerke
Bayer AG has entered into a long-term agreement with Wuppertaler Stadtwerke (WSW), the public utility company of Wuppertal in North Rhein-Westphalia, Germany, to procure electricity from renewable sources. This partnership…
FDA Grants Approval to Alecensa as the Primary Adjuvant Therapy for Individuals with ALK-Positive Early-Stage Non-Small Cell Lung Cancer
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) has announced that the U.S. Food and Drug Administration (FDA) has given approval for Alecensa® (alectinib), an anaplastic lymphoma kinase (ALK) inhibitor, to be…
Gepotidacin: Promising Oral Treatment for Uncomplicated Urogenital Gonorrhoea in Phase III Data
GSK plc (LSE/NYSE: GSK) has unveiled encouraging outcomes from the pivotal EAGLE-1 phase III trial concerning gepotidacin, a prospective first-in-class oral antibiotic offering a novel approach to combat uncomplicated urogenital…